Integrated molecular profiling of juvenile myelomonocytic leukemia.
暂无分享,去创建一个
H. Aburatani | S. Miyano | Y. Shiraishi | K. Chiba | S. Ogawa | H. Mano | Y. Okuno | G. Nagae | Kenichi Yoshida | M. Sanada | T. Ueno | S. Kojima | Kyogo Suzuki | H. Muramatsu | Yoshiyuki Takahashi | Masafumi Ito | A. Narita | N. Kawashima | N. Murakami | A. Watanabe | A. Hama | Hiroko Tanaka | H. Sakaguchi | Yinyan Xu | M. Hirayama | Xinan Wang | Norihiro Murakami | Toshihide Ueno
[1] Lixia Ding,et al. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center , 2019, European Journal of Pediatrics.
[2] S. Miyano,et al. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia. , 2019, Blood advances.
[3] C. Flotho. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia , 2019, Epigenetics.
[4] O. Haas. Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework , 2019, Front. Immunol..
[5] R. Wilson,et al. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression , 2017, Cell.
[6] J. Fletcher,et al. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1‐ALK fusions in epithelioid inflammatory myofibroblastic sarcoma , 2017, The Journal of pathology.
[7] S. Miyano,et al. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes , 2017, Genetics in Medicine.
[8] M. Takeuchi,et al. Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene , 2016, Blood Cancer Journal.
[9] F. Speleman,et al. LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. , 2016, Blood.
[10] S. Miyano,et al. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia , 2015, PloS one.
[11] A. Baruchel,et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.
[12] Andrew P. Feinberg,et al. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis , 2015, Nature Communications.
[13] T. Golub,et al. The Genomic Landscape of Juvenile Myelomonocytic Leukemia , 2015, Nature Genetics.
[14] John R. Haliburton,et al. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. , 2015, Blood.
[15] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[16] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[17] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[18] L. Cerroni,et al. Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions , 2014, The American journal of surgical pathology.
[19] David T. W. Jones,et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.
[20] S. Miyano,et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia , 2013, Nature Genetics.
[21] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[22] S. Ou,et al. Identification of ROS1 rearrangement in gastric adenocarcinoma , 2013, Cancer.
[23] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[24] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[25] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[26] M. Proytcheva. Juvenile myelomonocytic leukemia. , 2011, Seminars in diagnostic pathology.
[27] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[28] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[29] C. Plass,et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. , 2011, Blood.
[30] C. Messa,et al. Crizotinib in anaplastic large-cell lymphoma. , 2011, The New England journal of medicine.
[31] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[32] S. Shurtleff,et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Cole Trapnell,et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.
[34] A. Borkhardt,et al. ALK fusion genes in children with atypical myeloproliferative leukemia , 2010, Leukemia.
[35] Franco Locatelli,et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[37] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[38] M. Loh,et al. Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia , 2007, Leukemia.
[39] A. Wellstein,et al. Recruitment of insulin receptor substrate-1 and activation of NF-κB essential for midkine growth signaling through anaplastic lymphoma kinase , 2007, Oncogene.
[40] Wendy Schackwitz,et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.
[41] Alok J. Saldanha,et al. Java Treeview - extensible visualization of microarray data , 2004, Bioinform..
[42] S Miyano,et al. Open source clustering software. , 2004, Bioinformatics.
[43] Ming Zhou,et al. Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor , 2003, Genes, chromosomes & cancer.
[44] Mary L Marazita,et al. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. , 2002, American journal of human genetics.
[45] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .
[46] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .
[47] D. Pinkel. Differentiating juvenile myelomonocytic leukemia from infectious disease. , 1998, Blood.